Browse

Cytotoxic effects of pemetrexed in gastric cancer cells

Cited 24 time in Web of Science Cited 28 time in Scopus
Authors
Kim, Jee Hyun; Lee, Keun-Wook; Jung, Yeonjoo; Kim, Tai Young; Ham, Hye Seon; Jong, Hyun-Soon; Jung, Kyung Hae; Im, Seock-Ah; Kim, Tae-You; Kim, Noe Kyeong; Bang, Yung-Jue
Issue Date
2005-06-17
Publisher
Wiley-Blackwell
Citation
Cancer Sci. 2005 Jun;96(6):365-71.
Keywords
Antimetabolites, Antineoplastic/*pharmacologyBlotting, WesternCell DeathDNA DamageDNA RepairDrug Resistance, NeoplasmGene Expression Regulation/*drug effectsGlutamates/*pharmacologyGuanine/*analogs & derivatives/*pharmacologyHumansMembrane Transport Proteins/biosynthesis/physiologyPeptide Synthases/biosynthesis/physiologyReverse Transcriptase Polymerase Chain ReactionStomach Neoplasms/genetics/*pathologyThymidylate Synthase/biosynthesis/physiologyTumor Cells, Cultured
Abstract
Pemetrexed is a newly developed multitargeted antifolate with promising clinical activity in many solid tumors including gastric cancer. The aim of the present study was to evaluate the cytotoxicity of pemetrexed and its mode of interaction with cisplatin in gastric cancer cell lines, and to identify genes associated with sensitivity to pemetrexed. The cytotoxic activity of pemetrexed was assessed by tetrazolium-based colorimetric assay (MTT assay) and the interaction between pemetrexed and cisplatin was evaluated by the isobologram method. Western immunoblotting and real time RT-PCR analysis of thymidylate synthase (TS), folylpoly-gamma-glutamate synthetase (FPGS) and reduced folate carrier (RFC1) were performed in order to determine whether sensitivity to pemetrexed would be predictable by protein or mRNA expression levels. Pemetrexed was more cytotoxic than 5-fluorouracil, with IC50 between 17 and 310 nM in most of the gastric cancer cell lines examined and the pemetrexed/cisplatin combination resulted in additive or synergistic interaction. The protein expressions of TS, FPGS, and RFC1 were significantly associated with IC50 for 5-fluorouracil, but no such association was found for pemetrexed chemosensitivity. The mRNA expressions of RFC1, FPGS and other target and resistance related genes revealed no significant association with pemetrexed sensitivity. In conclusion, pemetrexed is active against gastric cancer cell lines and the pemetrexed/cisplatin combination showed a synergistic or additive interaction, supporting its clinical use in gastric cancer. Drug sensitivity toward pemetrexed could not be predicted by the expressions of TS, RFC1, or FPGS and we suggest that it is determined by interactions between multiple genes.
ISSN
1347-9032 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15958060

http://hdl.handle.net/10371/28174
DOI
https://doi.org/10.1111/j.1349-7006.2005.00058.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse